Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.

Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
28 Mar 2024
Historique:
received: 13 12 2023
revised: 21 02 2024
accepted: 28 02 2024
medline: 30 3 2024
pubmed: 30 3 2024
entrez: 29 3 2024
Statut: ppublish

Résumé

The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

Identifiants

DOI: 10.1016/j.cell.2024.02.041 PMID: 38552610
pubmed: 38552610
pii: S0092-8674(24)00244-7
doi: 10.1016/j.cell.2024.02.041
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1617-1635

Informations de copyright

Copyright © 2024 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Antonio Passaro (A)

Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Maise Al Bakir (M)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.

Emily G Hamilton (EG)

Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Maximilian Diehn (M)

Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Fabrice André (F)

Gustave-Roussy Cancer Center, Paris Saclay University, Villejuif, France.

Sinchita Roy-Chowdhuri (S)

Department of Anatomic Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Giannis Mountzios (G)

Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.

Ignacio I Wistuba (II)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Charles Swanton (C)

Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Oncology, University College London Hospitals, London, UK.

Solange Peters (S)

Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.

Classifications MeSH